Back to top

Image: Bigstock

J&J Stock Rallies More Than 10% in a Month: Time to Buy, Sell or Hold?

Read MoreHide Full Article

Key Takeaways

  • J&J shares have rallied, supported by stronger Q3 earnings and raised 2026 guidance.
  • Innovative Medicine growth and new drug launches are helping offset Stelara's patent expiration.
  • MedTech weakness, generic competition and talc litigation remain key challenges for J&J.

Johnson & Johnson (JNJ - Free Report) is outperforming the broader market. The rally appears to be supported by improving investor confidence in the company's growth prospects following its better-than-expected third-quarter 2026 earnings and upward revision to its full-year guidance.

J&J's third-quarter adjusted earnings of $2.59 per share exceeded the Zacks Consensus Estimate of $2.53, although revenues of $25.4 billion marginally missed expectations. Operational sales growth accelerated sequentially to 6% from 5.6% in the second quarter. Encouraged by the strong underlying business performance, management raised its 2026 adjusted earnings guidance to $11.05-$11.15 per share from $10.96-$11.11 and increased the lower end of its sales outlook to $101.0-$101.4 billion from $100.8-$101.4 billion. These positive developments likely contributed to renewed investor optimism.

Let’s understand the company’s strengths and weaknesses to better analyze how to play J&J stock in the post-earnings scenario.

J&J’s Innovative Medicine Business Remains a Key Growth Driver

J&J’s Innovative Medicines segment is the company’s primary growth engine. Innovative Medicine segment sales rose 6.9% on an organic basis in the first nine months of 2026, despite the loss of exclusivity (LOE) of the blockbuster drug, Stelara. Growth was driven by J&J’s key drugs like Darzalex, Erleada and Tremfya. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant/Lazcluze and Spravato also contributed significantly to growth.

J&J expects its Innovative Medicine segment to remain a key growth driver in future quarters. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato, Carvykti, Tecvayli and Erleada, as well as increased contribution from new launches like Icotyde, Rybrevant/Lazcluze, Imaavy and Inlexzo, which can offset the ongoing impact of Stelara biosimilar competition. J&J expects continued above-market growth for the Innovative Medicine segment.

The company is on track to be the #1 oncology company by 2030, with sales projected to exceed $50 billion.

New Products Strengthen J&J’s Long-Term Growth Prospects

J&J also rapidly advanced its pipeline in the past year, attaining significant clinical and regulatory milestones that will help drive growth through the back half of the decade. In the past year, it has gained approval for new products like Inlexzoh/TAR-200, a first-of-its-kind drug-releasing system, for treating high-risk non-muscle invasive bladder cancer; Imaavy (nipocalimab) for treating generalized myasthenia gravis and warm autoimmune hemolytic anemia and Icotyde (icotrokinra), an oral targeted peptide inhibitor of the IL-23 receptor, for treating moderate-to-severe plaque psoriasis (PsO). J&J markets Icotyde in partnership with Protagonist Therapeutics (PTGX - Free Report) .

J&J believes that nipocalimab has a pipeline-in-a-product potential and Icotyde/icotrokinra has the potential to revolutionize the treatment of plaque psoriasis with a once-a-day pill. It has the potential to be J&J’s largest product ever, with $10 billion in sales potential.

J&J is seeing strong launches of all these new drugs, Inlexzo, Icotyde as well as Imaavy.

J&J’s new cancer drugs, Carvykti, Tecvayli, Talvey and Rybrevant/Lazcluze are contributing significantly to top-line growth driven by market share gains. Combined, they generated $4.1 billion in sales in the first nine months of 2026.

J&J believes 10 of its new products in the Innovative Medicine segment have the potential to deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta, Inlexzo, Rybrevant, plus Lazcluze and Icotyde.

J&J’s MedTech Growth Remains Under Pressure

J&J’s MedTech business underperformed in both the second and third quarters of 2026. Weakness in Abiomed and persistent international headwinds have limited the benefits of its shift toward higher-growth cardiovascular markets.

Abiomed sales declined around 2% in both the second and third quarters as it faces lower procedure volumes and more cautious physician use of Impella following a U.K. clinical trial that questioned its benefit in certain high-risk procedures. Changes in patient selection have weighed on demand, introducing uncertainty around the business’s recovery.

Internationally, expanding volume-based procurement in China and J&J’s surgery transformation program continue to constrain Surgery sales. Competitive pressure in pulsed field ablation, particularly in Asia-Pacific, is limiting electrophysiology growth. Middle East disruptions have added pressure by affecting tender timing and customer ordering patterns.

Although MedTech’s operational sales growth slowed in the second and third quarters of 2026, MedTech performance is expected to improve in the fourth quarter of 2026 and strengthen further in 2027, supported by new product launches, cardiovascular innovations and a recovery in Surgery.

Patent Expiration of J&J’s Drug Stelara & Other Headwinds

J&J lost U.S. patent exclusivity of Stelara in 2025. Stelara was a key top-line driver for J&J, accounting for around 18% of J&J’s Innovative Medicine unit’s sales in 2024, before it lost patent exclusivity in 2025.

Several biosimilar versions of Stelara were launched in the United States in 2025 as the drug lost patent exclusivity.

Stelara’s LOE negatively impacted worldwide operational sales growth by 4.7% and Innovative Medicine segment sales by approximately 7.8% in the first nine months of 2026. In addition, J&J began facing generic competition for Simponi and Opsumit in mid-2026 as the drugs lost patent protection. Simponi biosimilars entered the European market in the second quarter, hurting third-quarter sales, while U.S. biosimilar launches are expected later this year. Opsumit also faced generic competition in the United States from late in the second quarter, weighing on third-quarter sales.

J&J faces approximately 76,500 remaining ovarian talc claims, which allege that its talc products contain asbestos that caused many women to develop ovarian cancer. J&J denies these allegations. Despite efforts to settle these matters, litigation has remained a longstanding overhang, generating substantial costs and negative headlines.

Though the issue is close to resolution, it has not yet been fully resolved. A proposed settlement could resolve nearly all remaining ovarian talc claims, but remains conditional. Announced in July 2026, the agreement includes an estimated $5.5 billion commitment and requires participation by plaintiff firms representing at least 95% of remaining claims, among other conditions. It covers existing claims only. The proposed payment schedule calls for up to $3 billion in 2027, with no additional payments due before 2028.

J&J Stock Price, Valuation and Estimates

J&J’s shares have outperformed the industry so far this year. The stock has risen 38.1% this year compared with 26.6% appreciation of the industry. The stock has also outperformed the sector and the S&P 500 Index, as seen in the chart below.

JNJ Stock Outperforms Industry, Sector & S&P 500

Zacks Investment ResearchImage Source: Zacks Investment Research

J&J is steeply valued. Going by the price/earnings ratio, the company’s shares currently trade at 24.83 forward earnings, higher than 19.89 for the industry. The stock is also trading above its five-year mean of 15.65. J&J stock is cheaper than only one large drugmaker, Eli Lilly (LLY - Free Report) .

JNJ Stock Valuation

Zacks Investment ResearchImage Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 earnings has declined from $11.17 to $11.12 over the past 30 days, while that for 2027 earnings has declined from $12.02 per share to $11.56 over the same time frame.

JNJ Estimate Movement

Zacks Investment ResearchImage Source: Zacks Investment Research

Stay Invested in J&J’s Stock

J&J’s biggest strength is its diversified business model, as it operates through pharmaceuticals and medical devices divisions, which reduces dependence on any single product or market. It has more than 275 subsidiaries and boasts 29 platforms or products with more than $1 billion in annual sales, with the aim of adding even more. Its diversification helps it withstand economic cycles more effectively. It also boasts strong cash flows and has increased its dividends for 64 consecutive years.

J&J continues to expect accelerated growth in 2026. Strength in Innovative Medicine is expected to persist, while MedTech performance is projected to improve in the fourth quarter. J&J is confident about achieving its target of generating more than $100 billion in revenues in 2026, with $74.8 billion already generated in the first three quarters. It expects sales growth to be even better in 2027, with a “line of sight” to double-digit growth by the end of the decade.

However, J&J’s MedTech business has underperformed in the past couple of quarters, raising concerns about the pace of its growth recovery. J&J also faces pressure from Stelara’s LOE and rising generic/biosimilar competition across several drugs. Though the litigation issue is close to resolution, it has not yet been fully resolved. Despite near-term challenges, J&J remains an attractive stock for long-term investors, supported by its diversified business, strong Innovative Medicine portfolio and promising pipeline.

Long-term investors may retain this Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in